Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Endosc. Feb 16, 2024; 16(2): 72-82
Published online Feb 16, 2024. doi: 10.4253/wjge.v16.i2.72
Table 1 Baseline patient characteristics before and after inverse probability of treatment weighting adjustment of patients treated by endoscopic submucosal dissection, surgery and definitive chemoradiotherapy
CharacteristicUnmatched



IPTW



d-CRTESDSurgeryP valued-CRTESDSurgeryP value
16992209157207
Sex Female5 (31.2) 39 (39.4) 53 (24.1) 0.021 (11.1) 24 (15.3) 61 (29.5) 0.228
Male11 (68.8) 60 (60.6) 167 (75.9) 8 (88.9) 133 (84.7) 146 (70.5)
Age< 6011 (68.8) 44 (44.4) 79 (35.9) 0.028 (88.9) 102 (65.0) 29 (38.2) 0.17
≥ 605 (31.2) 55 (55.6) 141 (64.1) 1 (11.1) 55 (35.0) 128 (61.8)
Tumor locationCervical03 (3.0) 0< 0.00101 (0.6) 00.047
Upper thoracic4 (25.0) 13 (13.1) 14 (6.4) 05 (3.2) 12 (5.8)
Middle thoracic4 (25.0) 42 (42.4) 111 (50.5) 1 (10.5) 27 (17.2) 99 (47.8)
Lower thoracic5 (31.2) 39 (39.4) 87 (39.5) 7 (77.4) 121 (77.1) 87 (42.0)
Multiple sources3 (18.8) 2 (2.0) 8 (3.6) 1 (8.5) 4 (2.5) 9 (4.4)
Tumor's longest diameter in cm< 35 (31.2) 66 (66.7) 93 (42.3) < 0.0011 (11.1) 31 (19.7) 93 (44.9) 0.077
≥ 311 (68.8) 33 (33.3) 127 (57.7) 8 (88.9) 126 (80.3) 114 (55.1)
Circumference ratio< 3/412 (75.0) 97 (98.0) 178 (80.9) < 0.0018 (88.9) 136 (86.6) 176 (85.0) 0.902
≥ 3/44 (25.0) 2 (2.0) 42 (19.1) 1 (11.1) 21 (13.4) 31 (15.0)
Depth of infiltrationM14 (25.0) 87 (87.9) 49 (22.3) < 0.0012 (22.2) 59 (37.6) 85 (41.1) 0.072
M22 (12.5) 4 (4.0) 9 (4.1) 6 (66.7) 3 (1.9) 9 (4.3)
M3-SM12 (12.5) 3 (3.0) 18 (8.2) 08 (5.1) 14 (6.8)
SM2-38 (50.0) 5 (5.1) 144 (65.5) 1 (11.1) 87 (55.4) 99 (47.8)
HistologyPrecancerous11 (68.8) 89 (89.9) 51 (23.2) < 0.0013 (33.3) 61 (38.9) 88 (42.5) 0.422
Well-differentiated SCC01 (1.0) 7 (3.2) 005 (2.4)
Moderately-differentiated SCC5 (31.2) 6 (6.1) 108 (49.1) 6 (66.7) 88 (56.1) 77 (37.2)
Poorly-differentiated SCC03 (3.0) 54 (24.5) 08 (5.0) 37 (17.9)
R0 resection or CRNo4 (25.0) 8 (8.1) 147 (66.8) < 0.0011 (11.1) 88 (55.9) 101 (48.8) 0.544
Yes12 (75.0) 91 (91.9) 73 (33.2) 8 (88.9) 69 (44.1) 106 (51.2)
ComplicationNo9 (56.2) 93 (93.9) 143 (65.0) < 0.0017 (77.8) 54 (34.4) 151 (72.9) 0.039
Yes7 (43.8) 6 (6.1) 77 (35.0) 2 (22.2) 103 (65.6) 56 (27.1)
Lymph node metastasisN014 (87.5) 96 (97.0) 196 (89.1) 0.0599 (100.0) 155 (98.7) 189 (91.3) 0.002
N1-22 (12.5) 3 (3.0) 24 (10.9) 02 (1.3) 18 (8.7)
Table 2 Complications before and after inverse probability of treatment weighting adjustment of patients treated by endoscopic submucosal dissection, surgery and definitive chemoradiotherapy
ComplicationUnmatched



IPTW




d-CRT
ESD
Surgery
P value
d-CRT
ESD
Surgery
P value
16992209157207
Radiation pneumonitisNo15 (93.8)99 (100.0)220 (100.0)< 0.0019 (100.0)157 (100.0)207 (100.0)0.783
Yes1 (6.2)00000
Aphonia No16 (100.0)99 (100.0)218 (99.1)0.5919 (100.0)157 (100.0)206 (99.5)0.745
Yes002 (0.9)001 (0.5)
PneumothoraxNo16 (100.0)99 (100.0)214 (97.3)0.2039 (100.0)157 (100.0)203 (98.1)0.537
Yes006 (2.7)004 (1.9)
DysphagiaNo15 (93.8)99 (100.0)219 (99.5)0.019 (100.0)157 (100.0)206 (99.5)0.439
Yes1 (6.2)01 (0.5)001 (0.5)
Anastomotic ulcer No16 (100.0)99 (100.0)215 (97.7)0.2659 (100.0)157 (100.0)204 (98.5)0.58
Yes005 (2.3)003 (1.5)
Pulmonary infectionNo16 (100.0)99 (100.0)206 (93.6)0.0229 (100.0)157 (100.0)197 (95.2)0.308
Yes0014 (6.4)0010 (4.8)
Anastomotic fistulaNo16 (100.0)99 (100.0)192 (87.3)< 0.0019 (100.0)157 (100.0)187 (90.3)0.133
Yes0028 (12.7)0020 (9.7)
Anastomotic or esophageal stenosis No13 (81.2)95 (96.0)181 (82.3)0.0049 (100.0)132 (84.1)178 (86.0)0.734
Yes3 (18.8)4 (4.0)39 (17.7)025 (15.9)29 (14.0)
MOFNo16 (100.0)99 (100.0)213 (96.8)0.1549 (100.0)157 (100.0)202 (97.6)0.489
Yes007 (3.2)005 (2.4)
Table 3 Incidence of hospitalization costs and salvage treatments after recurrence or metastasis before inverse probability of treatment weighting adjustment
Parameter
ESD, n = 98
Surgery, n = 220
d-CRT, n = 16
Follow up time40.0 (35.0-48.0)43.0 (34.0-53.75)32.5 (28.3-40.0)
Total cost25100130
Death toll1 (1.0)19 (8.6)3 (18.8)
Recurrence4 (4.0)3 8(17.3)4 (25.0)
Salvage measures after recurrence or metastasisSurgery (n = 3)Surgery (n = 5)Neoadjuvant chemo-radiotherapy (n = 1)
No treatment (n = 1)Neoadjuvant radiotherapy (n = 4)
Neoadjuvant chemotherapy (n = 8)
Neoadjuvant chemo-radiotherapy (n = 15)
No treatment (n = 7)